Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexa B Schrock

Showing results (81-90 of 130) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2023
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 StudyGiovanni Randon, Yoshiaki Nakamura, Rona Yaeger, et al.
Nature Communications|March 3, 2021
Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targetingZhenfang Du, Benjamin P Brown, Soyeon Kim, et al.
The Oncologist|March 16, 2018
Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care TestingJames H Suh, Alexa B Schrock, Adrienne Johnson, et al.
The Oncologist|May 2, 2019
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for TherapyAparna R Parikh, Yuting He, Ted S Hong, et al.
Gastroenterology|March 6, 2019
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as BiomarkersAatur D Singhi, Ben George, Joel R Greenbowe, et al.
Oncotarget|April 21, 2017
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomasRoman Groisberg, David S Hong, Vijaykumar Holla, et al.
JAMA Network Open|March 31, 2022
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate CancerRyon P Graf, Virginia Fisher, Janick Weberpals, et al.
JCO Precision Oncology|September 28, 2023
Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor ResponseJay A Moore, Kuei-Ting Chen, Russell Madison, et al.
NPJ Precision Oncology|December 9, 2022
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumorsJessica K Lee, Smruthy Sivakumar, Alexa B Schrock, et al.
European Urology Focus|June 1, 2019
Genomic Features of Metastatic Testicular Sex Cord Stromal TumorsAndrea Necchi, Gennady Bratslavsky, Oleg Shapiro, et al.
Pageof 13

Showing results (81-90 of 130) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 23, 2023
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 StudyGiovanni Randon, Yoshiaki Nakamura, Rona Yaeger, et al.
Nature Communications|March 3, 2021
Structure-function analysis of oncogenic EGFR Kinase Domain Duplication reveals insights into activation and a potential approach for therapeutic targetingZhenfang Du, Benjamin P Brown, Soyeon Kim, et al.
The Oncologist|March 16, 2018
Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care TestingJames H Suh, Alexa B Schrock, Adrienne Johnson, et al.
The Oncologist|May 2, 2019
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for TherapyAparna R Parikh, Yuting He, Ted S Hong, et al.
Gastroenterology|March 6, 2019
Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as BiomarkersAatur D Singhi, Ben George, Joel R Greenbowe, et al.
Oncotarget|April 21, 2017
Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomasRoman Groisberg, David S Hong, Vijaykumar Holla, et al.
JAMA Network Open|March 31, 2022
Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate CancerRyon P Graf, Virginia Fisher, Janick Weberpals, et al.
JCO Precision Oncology|September 28, 2023
Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor ResponseJay A Moore, Kuei-Ting Chen, Russell Madison, et al.
NPJ Precision Oncology|December 9, 2022
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumorsJessica K Lee, Smruthy Sivakumar, Alexa B Schrock, et al.
European Urology Focus|June 1, 2019
Genomic Features of Metastatic Testicular Sex Cord Stromal TumorsAndrea Necchi, Gennady Bratslavsky, Oleg Shapiro, et al.
Pageof 13